Cargando…
Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes
The purpose of this study was to evaluate and compare multiple daily injection (MDI) therapy of bolus insulin aspart and basal insulin glargine with continuous subcutaneous insulin infusion (CSII) with aspart in patients with type 2 diabetes mellitus (T2DM). It was assessed whether MDI was capable o...
Autores principales: | GAO, GUAN-QI, HENG, XUE-YUAN, WANG, YUE-LI, LI, WEN-XIA, DONG, QING-YU, LIANG, CUI-GE, DU, WEN-HUA, LIU, XIAO-MENG |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151650/ https://www.ncbi.nlm.nih.gov/pubmed/25187822 http://dx.doi.org/10.3892/etm.2014.1866 |
Ejemplares similares
-
Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
por: Lv, Wen-shan, et al.
Publicado: (2013) -
Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?
por: Rosinha, Patrícia, et al.
Publicado: (2022) -
Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019) -
Continuous subcutaneous insulin infusion therapy is associated with reduced retinopathy progression compared with multiple daily injections of insulin
por: Reid, Laura J., et al.
Publicado: (2021) -
Changes in Glycemic Control and Quality of Life in Pediatric Type 1 Diabetics
with Continuous Subcutaneous Insulin Infusion of Insulin Aspart Following Multiple Daily
Injection Therapy
por: Kawamura, Tomoyuki, et al.
Publicado: (2008)